THE WOOF OF WALL STREET

[linkvest]

IGPK....check out >>>>>>> merge with a billion in Revs just about completed.. HUGE MOVE-- Last day for the cheapies...
TheStockGuru
@Austria_9999
$IGPK : JFHE
Phase - 1 second part will be fill soon. EXPECTING otc 2023 annual and first quarter 2024 report will upload in disclosure, Attorney letter will updated, Business description and insiders name Changes and yield sign will remove Today end of the day or Tomorrow!!!!!
12:17 PM · Apr 23, 2024
876 Views

[ProfitScout]

$IVDN News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth

PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.

Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO
412-799-0350
[e-mail]
Website: http://www.insultexhousewrap.com

Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html

[QuicKtip]

$RONN NEWS IS OUT!

RONN, Inc. Agrees to Work with H2H to Integrate Their Patented Products into Ronn Inc. Global Projects$RONNhttps://t.co/6qyICbImPu pic.twitter.com/xkfKf12lNM

— Ronn Motor Group (Formerly $LPHM) (@leepharma) April 16, 2024

[QuicKtip]

$TREIF cse: $TRUE Treatment AI is quickly becoming the best assistant a doctor or nurse could ever ask for https://www.reddit.com/r/stockstobuytoday/comments/1btaegp/treif_cse_true_treatment_ai_is_quickly_becoming/

[QuicKtip]

$EFSH looks primed $90m in revenues FY 2023 with spinoff/dividend in play. Tiny float 5.9m https://mailchi.mp/broadstreetalerts/efsh-breakout-alert-95653?e=

[ProfitScout]

$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend

-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.

-- Company forecasts first commercial revenue in 2024 from sales of ketamine and related technologies. Company received advance of first milestone payments in 2024 for ongoing development of NRX-101 from Alvogen and Lotus Pharmaceuticals, Inc. (1975.TW)

-- Company announces new partnership around the first drug to potentially modify the underlying cause of schizophrenia

-- Data lock this week and top-line data expected this month, after completed enrollment of the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated 94% rater concordance, far in excess of industry norms and exceeded industry norms in medication compliance

-- Two new Investigational New Drug applications (INDs) accepted by the US Food and Drug Administration (FDA) for NRX-101 in Chronic Pain and Complicated UTI.

-- Data lock expected this week in 200-person DOD-funded trial of D-cycloserine (DCS), the key component of NRX-101, to treat chronic pain, conducted by Northwestern University

-- Grant of Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations for NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI); Publication last week of QIDP-qualifying data in a peer-reviewed journal. NRx is reviewing partnership options

-- Established HOPE Therapeutics to develop and launch IV Ketamine together with related technologies with FDA New Drug Application to be submitted this year. In advance of FDA approval, HOPE is partnered with national 503b and 503a pharmacies to address the ketamine shortage declared by FDA. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders via a tax-free dividend, and new investors; Term Sheets received from prospective anchor investors for $60 million of new investment, once publicly listed

-- HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients of IV Ketamine in treating severe and suicidal depression as the clinical basis for New Drug Application (NDA) for HTX-100 (IV Ketamine); expecting stability and CMC data sufficient for NDA filing by June 2024.

-- Added over $8 million in working capital, including an advance of a $5.1 million milestone payment from partners Alvogen, Inc. and Lotus Pharmaceuticals

-- Elected nationally recognized attorney in highly regulated industries, and healthcare specialist, Janet Rehnquist, Esq., to the Company's Board of Directors

-- Management has taken actions to address NASDAQ listing compliance and naked shorting of NRx securities

-- Management to host a conference call, April 1, 2024, at 8:30 AM ET

RADNOR, Pa., April 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.


"2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamline its operations with a 50% reduction in overhead costs, a 25% reduction in overall costs, and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives. We expect data from two key trials this month and predict our first commercial revenue by the end of 2024. Over the past year the Company has navigated the most challenging business environment in the history of the biotechnology industry. Despite unprecedented headwinds, we negotiated a critical commercial partnership for our lead compound in bipolar depression, while retaining rights to the far larger indications of chronic pain and PTSD," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We augmented our intellectual property portfolio to include the use of our lead compound in chronic pain and anticipate results of a 200-person efficacy trial that could open a multibillion dollar opportunity in this therapeutic area. We have acquired sufficient data on safety and efficacy of ketamine to support a New Drug Application for IV ketamine in acute suicidality. We established the foundation of a specialty pharmaceutical business around ketamine that we expect to yield positive cash flow by the end of 2024. Finally, we received unanticipated data supporting the use of our lead compound to treat complicated Urinary Tract Infection and Pyelonephritis, a condition that affects 3 million Americans and results in more than 15,000 deaths annually. We believe that NRx is poised for substantial growth in 2024 and look forward sharing further results in our conference call."

Fourth Quarter Clinical, Regulatory and Corporate Highlights

Development of NRX-101 for Treatment-Resistant Suicidal Bipolar Depression

The Company has announced today that it expects data lock this week and release of top line data this month in its Phase 2b/3 trial of NRX-101 in Suicidal Bipolar Depression. In 2023, the Company published results of a phase 2 trial demonstrating that oral NRX-101 extends the effect of IV ketamine in reducing both suicidality and depression in patients presenting to the hospital. This trial is designed to determine whether oral NRX-101 can reduce depression and suicidality in outpatients, which would be a massive broadening of the potential market for the drug. This potential expansion was guided by the Company's January 2023 meeting with the FDA in which NRx was advised to seek approval for NRX-101 as a drug for bipolar depression as a chronic, intermittent disease, a far broader indication.

With the completion of data collection, an unprecedented data integrity standard (94% agreement between site raters and central raters) has been achieved across the completed cohort of patients.

In 2023, the Company completed manufacture and Chemical Manufacturing Controls for NRX-101. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone allowed the Company to decrease its ongoing expenditure associated with manufacturing and development of chemical manufacturing controls.

During Q4 and in early 2024, the Company has continued to solidify its working relationship with Alvogen and Lotus, and begun working in unison to plan the final development and commercialization of NRX-101. These partners recently advanced $5 million of the first milestone to the Company. As previously announced, a successful readout from this trial and FDA interaction will trigger an additional $4 million milestone payment together with transfer of future development costs to our partner. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on Net Sales.

NRX-101 for Treatment of Chronic Pain:

The Company has previously detailed the scientific basis for treatment of chronic pain with DCS as outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company's Scientific Leadership (Sappko, et. al.). In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain.

Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first N-methyl-D-aspartate (NMDA)-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.)

The Company is advised that data lock will occur this week in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Top line results will follow. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.

Spin out of HOPE Therapeutics and progress towards an NDA for NRX-100 (ketamine) in the treatment of suicidal depression.

When NRx met with the FDA in January 2023, the agency strongly encouraged the Company to develop NRX-100 (IV Ketamine) as a labeled drug, rather than rely on prior stabilization of suicidality and depression achieved via the common clinical practice of infusing generic ketamine compounded in licensed pharmacies. Shortly thereafter, the FDA issued the first of two advisory letters warning physicians against using compounded forms of ketamine and began a program of rigorous inspections of such pharmacies. Although there was once an expectation that intranasal administration of ketamine would be effective in treating suicidality, the attempts to demonstrate the clinical efficacy of nasal racemic ketamine for acute suicidality have not succeeded.

Accordingly, in Q3 the Company finalized a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. (Link)

In the fourth quarter, the company similarly licensed data from Columbia University. In this trial, Dr. Michael Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880701/.

The patient-level deidentified data from both studies have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company believes that these randomized, blinded prospective trials encompassing nearly 240 participants, when submitted for review at a patient level could be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of 2Q23.

Submission of an NDA for the use of IV Ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. This formulation is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features.

On March 30, 2024, the Company booked first commercial delivery of ketamine manufactured to 503b pharmacy standards from Nephron. HOPE will be distributing this presentation to qualified ketamine clinics in coordination with Nephron under Nephron's 503b pharmacy license in light of the current FDA-declared drug shortage of ketamine, starting this month (April 2024).

Treatment of Urinary Tract Infection (UTI) and Urosepsis:

Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. D-cycloserine fell out of favor as an antibiotic in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of effective first and second-generation antibiotics.

During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally-mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA.

In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.). Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.

Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status.

The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year (Lodise, et. al.) in the US and potential pricing of over $3,500/course of therapy.

Cash runway and financing

The Company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein.

Financial Results for the Quarter and Year Ended December 31, 2023

For the three months ended December 31, 2023, we at NRx Pharmaceuticals reduced our net loss from $10.2 million in the final quarter of 2022 to $4.3 million in 2023, representing nearly a 60% improvement year over year. For that same period, we reduced research and development expenses from $4.5 million in 2022 to $2.5 million in 2023, while substantially improving and finalizing our clinical trial enrollment. The $2.0 million decrease is related primarily to a decrease of $1.1 million in clinical trial expenses, $0.6 million in stock-based compensation, and $0.2 million in consulting and personnel wage costs. Also in that 3 month period we recorded a 67% reduction in general and administrative expenses, from $5.4 million in 2022 to $1.8 million in 2023. The decrease of $3.6 million is related primarily to a decrease of $1.3 million in insurance expenses, $1.3 million in stock-based compensation, $0.5 million in employee expenses, $0.2 million in legal and professional consulting fees, and $0.2 million in franchise tax expenses.

For the year ended December 31, 2023, NRx Pharmaceuticals reduced its net loss to $30.2 million compared to $39.8 million in the prior year. These efficiencies represent an improvement in net loss of nearly $10.0 million year over and a 20 cent, or 34%, improvement in net loss per share year over year. Over that annual period we recorded $13.4 million of research and development expenses compared to $17.0 million for the same period in 2022 representing a 21% decrease year over year. The decrease of $3.6 is related primarily to a decrease of $2.1 million in clinical trial and development expenses, $0.9 million related to fees paid to regulatory and process development consultants, $0.8 million in stock-based compensation while offset by a $0.2 million increase in patent costs as our patent portfolio has expanded.

Please note that the improvement in G&A expenses is even larger than the improvement in other areas. We decreased G&A by $13.1 million, from $27.3 million in 2022 to $14.2 million in 2023, nearly a 50% decrease year over year.

As of December 31, 2023, we had $4.6 million in cash and cash equivalents. Over the first three months of 2024 we improved our access to working capital by $8 million total, representing $2.9 million from equity sales and $5.1 million from the Alvogen milestone advance, while reducing our corporate indebtedness by 50% as shown in our financial statements.

We continue to implement operational efficiencies to extend runway and focus on our path to generating revenue. We believe that the near-term delivery of clinical trial data and the planned the launch of HOPE Therapeutics will be defining events in the second quarter of 2024.

Conference Call and Webcast Details

A live webcast of the conference call will be available on the Company's website at 8:30 a.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453 or internationally 1-201-389-0920.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

https://c212.net/c/img/favicon.png?sn=CL76439&sd=2024-04-01 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302104468.html

SOURCE NRx Pharmaceuticals, Inc.

[ProfitScout]

$NRXP News: NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.

The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders. Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced." He will present an overview of the rapid and dramatic efficacy of Ketamine in the treatment of acute suicidality as well as recent science documenting the potential for neurotoxicity with long-term CNS side effects if ketamine is used without appropriate safety controls as a long-term drug.

"HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality. It is an honor for our company to be invited to share a platform with those who have established this field of science and who may forever change the outlook and future path of patients who suffer from suicidal depression and PTSD," said Dr. Javitt.

Ketamine 2024 Conference Presentation

When: Monday, March 25th, 2024

Time: 1:40-2:00 PM GMT

Title: Ketamine: The Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

[Tiger Money]

Awesome! $AGSS

https://www.otcmarkets.com/stock/AGSS/news/AmeriGuard-Security-Services-Inc-Awarded-Prestigious-Contract-by-US-Department-of-Veterans-Affairs-for-Non-Emergency-Med?id=434252

[QuicKtip]

$TWOH, DEBT REDUCTION AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free

[QuicKtip]

$TWOH, DEBT REDUCTION AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free

[NYBob]

Mark #13 to You
TIA

[NYBob]

Mark #3 to You
TIA

[Skydive21]

FIRST TELLURIUM’S NEW THERMOELECTRIC DEVICE DEMONSTRATED AT RECENT PRESENTATION
March 13, 2024
Tyrone Docherty
With robust applications for solar power, combustion engines, greenhouses and more, the device is described as a “game changer” by industry insider.

Vancouver, BC, Canada, March 13, 2024 – First Tellurium Corp. (CSE: FTEL, OTC: FSTTF), reports that investors can view a video of the Company’s recent presentation in Vancouver, which included a demonstration of the new tellurium-based thermoelectric generator developed by First Tellurium’s 51%-owned thermoelectric-focused research and development company PyroDelta Energy (“PyroDelta”). Patents for the device have been applied for in Canada and the United States.

The generator was presented to the gathering by PyroDelta co-founder Michael Abdelmaseh, who demonstrated how the device generated power from simple changes in temperature, producing energy from the heat of human skin as well as from ice. However, the generator’s primary and unique advantages come from its robust construction, low manufacturing costs, light weight and ability to withstand temperature extremes.

“Thermoelectric devices have been around for a very long time,” said Abdelmaseh. “However, none of them are suited for long-term, commercial applications that can tolerate high heat. This device can withstand temperatures of six hundred degrees Celsius.”

“This is a Game Changer”

Don Freschi, President and CEO of Fenix Advanced Materials, an industry expert who supplies metals for other thermoelectric devices, commented to the audience, “This is a game changer. I’ve never seen anything like this.”

Freschi noted that by using ultra high-purity tellurium, the device could achieve exceptional efficiencies. “Using lower purity metals, we could charge an iPhone with a tiny device,” said Freschi. “But going to high purity (99.99999 percent) tellurium, this device could power a few households.”

“The generator uses mainly tellurium,” said First Tellurium President and CEO Tyrone Docherty. “This is why Michael contacted us. He was previously in talks with a large, European luxury car manufacturer. However, believing that reliable supplies of high-purity tellurium would be key, Abdelmaseh approached First Tellurium to partner for device manufacturing.”

Production-Ready

Abdelmaseh reported that the device is ready to enter production mode. “We are done with the research and development,” said Abdelmaseh. “We have the data that shows the efficiency, and we are ready to produce it.”

As Abdelmaseh explained, PyroDelta has applied for patents on two configurations. One increases the efficiency of solar panels. The other can replace radiators and alternators in internal combustion engines, making them far more efficient and saving fuel.

Solar Panels Far More Efficient and Deployable

For solar applications, the thermoelectric device can expand the range of locations for solar power deployment, especially for sites with low sunlight and long nights. “When solar is combined with thermoelectric, you can cut down drastically the amount of battery storage required,” said Abdelmaseh.

Automobile Alternators Could Become Obsolete

In automotive applications, the device in a pipe form requires a simple retrofit to internal combustion engines without retooling assembly lines. “If you introduce anything disruptive to an existing production line that costs, say, two hundred million dollars,” said Abdelmaseh, “it’s doomed to failure. Existing vehicles can use new thermoelectric radiators, and they will generate electricity just from the heat differential of the hot liquid going through the (thermoelectric pipe) radiator and the air cooling it from the outside.” PyroDelta is presently building a thermoelectric radiator with a 1-kilowatt capacity for vehicle retrofit.

Added Abdelmaseh, “This can make your alternator obsolete. You can use the energy that’s coming out of your radiator to power all your onboard accessories—your AC, your radio, everything. This will raise the efficiency of your vehicle.”

Making Combustion Engines Significantly More Efficient

Abdelmaseh noted that today’s combustion engines generate peak efficiency of about 30-35 percent from a gallon of gas. Replacing the radiator with the thermoelectric pipe device could theoretically add an additional 12 percent in efficiency. Conservatively, Abdelmaseh estimated the added energy would total at least six-to-eight percent.

According to the U.S. Energy Administration (EIA), Americans used about 134 billion gallons of gas in 2022. An eight-percent savings would amount to over 10 billion gallons per year.

Greenhouse, Commercial Properties and Industrial Waste

Abdelmaseh also identified greenhouses, commercial properties, industrial waste and manufacturing plants as potential markets for the thermoelectric device. “Any facility with waste heat can generate electricity and lower power costs,” he said, adding that the robust construction of the device makes it ideal for harsh environments with high extremes of heat and/or cold. “The more it can withstand extremes, the more efficient it becomes,” said Abdelmaseh.

PyroDelta estimates that deploying the device in greenhouses could provide energy savings of 30 percent.

Extending Drone Battery Life

Due to the device’s small size and low weight, another large potential market would be powering drones. According to Abdelmaseh, the device as drone range extender, weighing only 70 grams (2.5 ounces), could extend a drone’s range from 15 minutes to an hour. The increased battery life could open up vast new markets, including defense and a wide range of commercial uses.

Docherty noted, “The small size of this device, which in this case is only about 50 millimeters by 100 millimeters (approximately two inches by four inches), combined with its light weight, makes it ideal for the drone market. However, any market that could benefit from these advantages of size, weight and power generation becomes accessible to us.”

First Tellurium will provide additional information about the device and potential markets in upcoming news releases.

About First Tellurium Corp.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in Indigenous territory with sustainable exploration.

Our Klondike tellurium-gold property in Colorado and polymetallic Deer Horn Project in British Columbia anchor a diversified search for metals, working in alliance with Indigenous peoples, NGOs, governments and leading metals buyers. This is the future of mineral exploration: generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to and supports the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and in particular the fundamental proposition of free, prior and informed consent. First Tellurium is listed on the Canadian Stock Exchange under the symbol “FTEL” and on the OTC under the symbol “FSTTF”. Further information about FTEL and its projects can be found on www.firsttellurium.com.

On behalf of the board of directors of First Tellurium Corp.



“Tyrone Docherty”

Tyrone Docherty

President and CEO



For further information please contact:



Tyrone Docherty

604.789.5653

[e-mail]
Twitter: @TelluriumCorp
www.firsttellurium.com

[linkvest]

SONX....GAME CHANGER.. this is the time to buy before Monday gets here. **** Sonendo, Inc... conference call for the Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 1, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.

Investors interested in listening to the conference call may do so by dialing [phone] for domestic callers or [phone] for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.

[Magnum7419]

$AHRO Analyst Target Prices $AHRO LOW TARGET 10.30


HIGH TARGET 10.3000 MEAN TARGET 10.3000 LOW TARGET 10.30

Wow and I thought .10 cents was great :)

Authentic Holdings Inc ($AHRO)
0.0008 -0.0001 (-11.11%) 03/01/24 [OTC US]
ANALYST RATINGS for Fri, Mar 1st, 2024Notes Alerts Watch Help
Analyst Target Prices
HIGH TARGET 10.3000 MEAN TARGET 10.3000 LOW TARGET 10.30 0052 WK HIGH 0.0020 52 WK LOW 0.0001
Average Analyst Ratings
3 MTHS AGO
Strong Buy
5.00

RATINGS VALUES: Strong Buy =5 Moderate Buy =4 Hold =3 Moderate Sell =2 Strong Sell =1
Ratings Breakdownhttps://www.barchart.com/stocks/quotes/AHRO/analyst-ratings
Bullish
BULLISH

[QuicKtip]

$CBDW -- 1606 Corp's Partnership with Cannasite Sparks Rapid Revenue Growth for CBDW's AI-Driven Chatbot

[QuicKtip]

$CBDW 1606 Corp CEO @ CES Making Deals!

[QuicKtip]

$TWOH Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://finance.yahoo.com/news/two-hands-corporation-launches-sports-155000347.html

[QuicKtip]

Mr. Wing-Fai Ng, Group President, $AGBA Group Holding Limited said “The successful completion of our private placement is an accomplishment that speaks volumes about the strength and potential of our business. The infusion of new capital at this opportune moment will put us in a supreme position to capture growth that we now see coming in 2024.” https://finance.yahoo.com/news/agba-celebrates-major-milestone-successful-140000317.html

[QuicKtip]

$SYNX Silynx videos are meant to inform our brave,
hardcore users on the best practices in using our
gear in the field. Our mission is to keep you safe
and connected as you do the hard work on the front
lines for the rest of us.

https://www.silynxcom.com/our-videos/

[Magnum7419]

Pls let Sporty know about $AHRO

[QuicKtip]

$CBDW Trifecta of Sales and Marketing Excellence at 1606 Corp! https://cbdw.ai/trifecta-of-sales-and-marketing-excellence-at-1606-corp/

[linkvest]

UCAR GREAT NEWS.... https://www.stocktitan.net/news/UCAR/u-power-limited-enters-into-a-memorandum-of-understanding-with-9awsqnctdkw1.html

[srm4u]

impressive

[Trend-Setter]

ELTP - Rising otc gem of a lifetime!
https://bnnbreaking.com/finance-nav/elite-pharmaceuticals-shatters-expectations-with-67-revenue-growth-in-q3-2024

Latest Earning's CC - Feb. 15, 2024
"Last question, let’s see, company’s futures, what would Mr. Hakim say is the likelihood that Elite will uplift to NASDAQ within the next five years? What would Mr. Hakim say is the likelihood that Elite will get bought out by a large arrival within the next five years?"

"Two things I’ll say to that. One, cut that prediction in half or more than half. Five years is a very long time to do either. We are at a point where our fundamentals are solid, and we are in a growth stage, as I said earlier. We’re not flattening out at $30 million and $40 million. We skip the 40s, went to 50s. And we’ll talk in June once I have a little more data, what I expect for the future.

But definitely, the year after, we’re going to beat that. And the year after, we’re going to be that. So we’re at a growth stage. So the fundamentals are looking great, a buyout is looking great. And five years is way too long for that. So I would say either of this will happen in a couple of years." - CEO N.Hakim
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173856451

[linkvest]

SONX... time to grab these cheapies before it gets relisted with NYSE possible next week. Was $10 a share then.

[QuicKtip]

$TMGI Try one of our new Bundles! Matched products for maximum effectiveness, at a savings! http://SimplyWhim.com

Try one of our new Bundles! Matched products for maximum effectiveness, at a savings! https://t.co/hx8dws8fQM pic.twitter.com/BYN9QDR4uP

— Whim (@SimplyWhim) February 12, 2024

[QuicKtip]

$SMME the SmartMetric biometric credit/debit card has an inbuilt hardware based live fingerprint detection created by SmartMetric and only available on the SmartMetric biometric credit/debit card. https://finance.yahoo.com/news/smartmetric-says-gen4-self-powered-144000504.html

[QuicKtip]

$CAUD @CollectiveAud with wonderful host @MarketJane at the @Nasdaq

No better way to spend a snowy NYC morning than with this guy talking about what we are building, and how we are disrupting @CollectiveAud with our wonderful host @MarketJane at the @Nasdaq

Thank you for being such a wonderful host Jane. $CAUD #advertising #adtech pic.twitter.com/azHrUKsCOu

— Peter Bordes (@PeterBordes) February 13, 2024

[Jaxxm]

CBIA Cancelling 581 Million Common shares

581,045,000 of these shares are the subject of a rescission agreement and are to be tendered for cancellation in the near future. Following such cancellation, the issued and outstanding shares of the Company’s common stock will be 2,206,681,572 shares, assuming not additional issuances are made. Once the cancellation is effected, the entry set forth below will be presented in the table of issuances/cancellations above

Page 8 and 24

https://www.otcmarkets.com/otcapi/company/financial-report/391929/content

[ProfitScout]

$SRM Feature Article: Strong Consumer Market for NASDAQ Coming Off Original $5 IPO with New Toy & Souvenir Products for Top Clients: $SRM
Click here:
https://www.einpresswire.com/article/686503802/strong-consumer-market-for-nasdaq-coming-off-original-5-ipo-with-new-toy-souvenir-products-for-top-clients-srm

[QuicKtip]

$CBDW $1606 Corp.'s CEO Interviewed by RedChip Small Stocks, Big Money™ Show regarding AI https://finance.yahoo.com/news/1606-corp-ceo-interviewed-redchip-133000578.html

[QuicKtip]

Nitches (OTCPink: $NICH) Unveils Exciting Flavor Profiles for 2024 https://www.reddit.com/r/stockstobuytoday/comments/1ahcnrw/nitches_otcpink_nich_unveils_exciting_flavor/

[QuicKtip]

$ARQ $ARBTF Argo's Oil Operations Update https://finance.yahoo.com/news/argos-oil-operations-145900720.html

[QuicKtip]

NxGen Brands Inc. $NXGB Sets Date for 'Mad Scoops Anabolic Protein' Product Launch & Announces Product to Include Innovative 'Inclusions'
https://www.reddit.com/r/stockstobuytoday/comments/1ah7zn7/nxgen_brands_inc_nxgb_sets_date_for_mad_scoops/

[ProfitScout]

$SRM Entertainment Showcases New Products at the 2024 Las Vegas Winter Market Gift Show
January 28th - February 1st Showroom C972, C975

JUPITER, FL, Jan. 29, 2024 (GLOBE NEWSWIRE) -- SRM Entertainment, Inc., (Nasdaq: SRM) (the “Company” or “SRM”) will introduce a new line of products at the iconic Winter Market 2024 in Las Vegas from January 28 through February 1st, featuring our new Zoo Animals assortment, Sealife assortment and custom designs.

The SRM Design Team’s creativity will be featured as we showcase our custom design capabilites and introduce our new Zoo Animals and Sealife poduct assortment lines at the Las Vegas Market Winter Show, a leading industry trade show (Showroom C972 & C975).

"The Las Vegas Market is the perfect West Coast venue to feature the creativity and experience of the SRM Team" said Rich Miller, CEO of SRM Entertainment. “We’re excited to showcase new products and design innovations that feature SRM’s imaginitive capabilities for 2024 and beyond.”

About SRM Entertainment, Inc.

SRM Entertainment, Inc. designs, develops and manufactures custom toys and souvenirs for the world's largest theme parks and entertainment venues. The Company provides exclusive custom products that are available worldwide at venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld and other attractions. Additionally, SRM recently launched its retail product line which includes patented SMURFS Sip with Me cups.

Caution Regarding Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the “Risk Factors” section of the registration statement for the Offering filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.

Media and Investor Relations

[e-mail]
(407)-230-8100
website: SRMentertainment.com

https://www.globenewswire.com/newsroom/ti?nf=OTAyNjY3NyM2MDQxNDA0IzUwMDExODAxNA==
https://ml.globenewswire.com/media/ZTQzZTQ4ZTQtN2U3NS00MTE4LWFiODUtZTRmNzg3ZjIzNWU2LTUwMDExODAxNA==/tiny/SRM-Entertainment-Inc-.png

Source: SRM Entertainment, Inc.

[QuicKtip]

$CBDW 1606 Corp. has successfully developed a groundbreaking AI solution tailored to address the unique customer educational challenges faced by CBD merchants. https://finance.yahoo.com/news/1606-corp-accounts-skyrocket-december-133000797.html

[QuicKtip]

1606 Corp. (OTC: $CBDW): Revolutionizing CBD Customer Service with AI Innovation

[QuicKtip]

Spectral AI Ltd (NASDAQ:MDAI) founder and CEO Wensheng Fan speaks to Thomas Warner from Proactive after the medical-focused artificial intelligence company announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.

[Golden Cross]

$MGRX Is Launching “PRIME”, Powered By KYZATREX Capsules, For An FDA Approved ORAL #Testosterone Replacement Therapy (#TRT) Product!
Link: https://globenewswire.com/news-release/2023/12/13/2795461/0/en/MANGOCEUTICALS-TO-INTRODUCE-PRIME-POWERED-BY-KYZATREX-%ef%b8%8f-CIII-TESTOSTERONE-UNDECANOATE-CAPSULES-FOR-AN-FDA-APPROVED-ORAL-TESTOSTERONE-REPLACEMENT-THERAPY-TRT-PRODUCT.html

The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as ‘Prime’ by MangoRx

Dallas, Texas & Raleigh, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals ("Marius") to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, 'PRIME' by MangoRx.

PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.

TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body's natural diurnal rhythm allowing for peak performance early in the day.

Twice daily oral TRTs offer painless administration, promote steady absorption, lower SHGB levels, increase free T levels to give the body more usable testosterone, and work with the body's natural diurnal rhythm. Oral softgels are also convenient, mess-free, and discreet.

Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.”

PRIME by MangoRx will bring KYZATREX to patients spanning 48 states through the Company’s telemedicine platform, which is optimized to deliver a smooth medical prescription process, including blood work and synchronous telehealth visits with a fully licensed prescribing physician. Orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx’s URAC accredited mail order partner pharmacy directly to the patient’s doorstep.

Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with our established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. We are extremely fortunate to be working with Marius and to be one of only a few companies with access to this innovative product. With our established marketing and telemedicine infrastructure in place, we are ready to hit the ground running and take PRIME to patients in need across the country next month."

Testosterone deficiency affects approximately four in ten men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society.3,4 Between 10% and 40% of men worldwide suffer from low testosterone levels.5

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

About Marius Pharmaceuticals

Marius Pharmaceuticals strives to better the lives of patients by focusing on therapies designed for hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system. For more information, please visit www.mariuspharma.com.

About KYZATREX® (testosterone undecanoate)

KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) and indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in symptoms of low testosterone, including quality of life, energy/fatigue, erectile function, sexual intercourse, and mood. The most common side effect reported in ≥2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established.

[ProfitScout]

$IVDN (16 million float): Superior Advancement for High Energy Efficiency Insulation Drawing Rising Interest and Commercial Demand; New International Patent Application Accepted to Maximize Marketing Potential
Feature Link:
https://markets.financialcontent.com/startribune/article/getnews-2023-12-28-superior-advancement-for-high-energy-efficiency-insulation-drawing-rising-interest-and-commercial-demand-new-international-patent-application-accepted-to-maximize-marketing-potential-ivdn

From the article:

Very Small Stock Structure of Only 37 Million OS / 16 Million Float

- Sole Maker of Patented Insultex® Insulation Delivering Energy Saving Performance Far Superior to All Competition.

- Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating Plus a Water Vapor, Air, and Wind Barrier and Other Superior Benefits.

- World International Patent Organization Application Accepted to Maximize Global Marketing Opportunities.

- "Leader in Green Assets" LIG Assets, Inc., in Association with Robert Plarr, Signs Sales and Licensing Agreement with IVDN.

- Insultex House Wrap® Already Being Installed by LIG Assets in Conjunction with Their Plans to Acquire Firm Doing $100-200 Million in Annualized Sales.

- Over a Dozen New Sales Accounts were Added in the Fiscal Fourth Quarter with Orders Being Fulfilled for Superior Insultex® House Wrap.

- New Building Codes Require Higher Insulation Performance and IVDN Meets or Exceeds These New Standards Where Many Competitors Do Not.

- Increased Order Fulfilment Capabilities Recently Added with Plans for Further Enhancement to Handle Increasing Customer Demand.

- New Sales Accounts Include Large-Scale Commercial Modular Construction Firm Guerdon, LLC.

- Greater Energy Savings from Insultex® Insulation Delivers Substantial Economic Gains and Tax Credits for the User and Also Carbon Reduction for the Environment.

- Insider Buying from Board Member with Lockheed Martin & NASA Background.

[Skydive21]

Thermal Energy International Reports 71% Revenue Growth and Improved Profitability in Second Quarter
01/25/2024 7:01:00 AM
Bid and Ask @ .20. That's twenty cents!! Why?


Turn-Key Projects and Custom Equipment businesses up significantly year-over-year


Ottawa, Ontario--(Newsfile Corp. - January 25, 2024) - Thermal Energy International Inc. (TSXV: TMG) (OTCQB: TMGEF) ("Thermal Energy" or the "Company"), a provider of innovative energy efficiency and carbon emission reduction solutions to major corporations around the world, today reported its financial results for the second quarter ended November 30, 2023. All figures are in Canadian dollars.


Highlights:



Revenue: $7.1 million, a 71% increase from the same quarter last year

Gross profit: $3.5 million, a 97% increase from the same quarter last year

EBITDAi: $830 thousand compared to a loss of $28 thousand in the second quarter of last year

Net income: $486 thousand compared to a loss of $266 thousand in the same quarter last year

Order intake: $12.8 million for the quarter and $22.2 million for fiscal 2024 year-to-date (as at January 23, 2024)

Order backlogii: $17.5 million as at Nov 30, 2023 and $23.6 million as at January 23, 2024

[yerboss]

🎯#KNIT:OTC AI Acquisition News!🎯
💎Kinetic Group, Inc. Finalizes Acquisition of Binnops US Technologies Inc- An AI Company Providing Digital Transformation Solutions to Enterprises💎
👉Full PR http://tinyurl.com/yvet5cuo
👉Visit Them https://www.knitgrp.com/
🎯Microcap (for now)
🎯Tiny Float - 68K Shares At DTC! Squeeze?
🎯A Sample Of Their Current Clients Include: Chevron #CVX, Shell Oil #SHEL, US Department of State, SNC-Lavalin #SNCAF, Bechtel Group, many more.....
🎯Uplist Planned for 2024

💎MIAMI, Jan. 3, 2024 /PRNewswire/ -- Kinetic Group Inc., (OTC: KNIT), www.knitgrp.com, has acquired 100% of US based BINNOPS US TECHNOLOGIES INC in an all stock transaction. Binnops is a leading provider of profitable artificial intelligence software solutions to enterprises in the energy, manufacturing, transportation, aeronautical, retail and government sectors.
The acquisition positions KNIT as a leading provider of Digital Twins, Smart Assets, AI predictive analytics and Metaverse engagement to enterprises and retail clients. Delivering transformative digital technologies since 2016, Binnops has provided customizable solutions to leading Fortune 500 companies, across the globe, with lifetime contract revenue of over six million dollars. As a result, KNIT acquires a robust portfolio of clients, spanning the globe, and a pipeline of business opportunities. With expected sales of US$5.1M and EBITDA of US$2.8M, in the first year after the acquisition, Binnops' smart asset solutions drive real digital transformation solutions that enhance an enterprises' margins by increasing efficiency and productivity and managing risk through predictive analytics. KNIT can go beyond the hype and deliver real results...........

[QuicKtip]

$TWOH - Sports Illustrated Nutrition's new line of protein bars come in four flavors - Triple Chocolate, Cookies & Cream, Blueberry White Chocolate and Strawberry Chocolate. https://twohandsgroup.com/twoh

[Golden Cross]

$KATX RM Play--What is moving the PPS Here ⬇️

[Solarman]

$GGSM and $MMMW no toxic debt. $MMMW interesting news today.

[Jaxxm]

$GGSM(.0008)~Revenue & Profit, NO notes & debt~DD

$1.99 Million cash,
No debt,
No convertible notes,
8.76 million dollars asset.
Q1 + Q2= 5.29 million dollars Revenue,
Q1+ Q2= 1.31 million dollars Net profit.

https://www.otcmarkets.com/otcapi/company/financial-report/383292/content
..............
GGSM CEO and President holds about 26.71 % of common shares.469 million shares

https://www.otcmarkets.com/otcapi/company/financial-report/383292/content
...............

GGSM 1.3 billion A/S reduced. Now 2.2 billion

https://www.otcmarkets.com/stock/GGSM/security

It was 3.5 billion

https://www.otcmarkets.com/otcapi/company/financial-report/383292/content

..............

Brick mortar business.. they owns a family resort and charter boats.

https://www.makiboat.com/

[BottomBounce]

1 oz of Rhodium bullion physical metals is now $3,900 up +100.00 Today

[Golden Cross]

$BLEG Loading up for Growth-->>>

Secured a $1,000,000 line of credit under a fixed interest rate and confirms there will be no reverse split.

BLEG previously announced it would retire 1.6 Billion shares, $BLEG is not stopping!
https://www.prnewswire.com/news-releases/branded-legacy-inc-secures-1m-line-of-credit-affirms-no-reverse-split-and-previews-upcoming-investor-engagements-301980129.html

[QuicKtip]

$NICH Nitches Corp Announces Exciting New Website for Tover spirits: Unveiling a Sleek New Website for Spirit Enthusiasts https://finance.yahoo.com/news/nitches-corp-announces-exciting-website-120000218.html